| 2933.99.79 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¡é/kg + 52% |
| 2934.10.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4¡é/kg + 52% |
| 2934.20.40 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¡é/kg + 52% |
| 2934.30.43 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4¡é/kg + 52% |
| 2934.99.03 | 00 | 2-Acetylbenzo(b)thiophene; 3-Methylene-7-(2-phenoxyacetamido)- cephan-4-carboxylic acid, p-nitrobenzyl ester, 1-oxide; and Naphth[1,2-d]-[1,2,3]-oxadiazole-5-sulfonic acid and its sodium salt | kg | Free | | 15.4¡é/kg + 52% |
| 2934.99.39 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¡é/kg + 52% |
| 2934.99.70 | 00 | Morpholinoethyl chloride hydrochloride; 2-Methyl-2,5-dioxo-1-oxa-2-phospholan; and (6R-trans)-7-Amino-3-methyl-8-oxo-5- thia-1-azabicyclo[4.2.0]-oct-2-ene-2- carboxylic acid | kg | Free | | 30.5% |
| 2935.00.75 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¡é/kg + 57.5% |
| 2936.29.10 | 00 | Folic acid | kg | Free | | 15.4¡é/kg + 49% |
| 2942.00.03 | 00 | [2,2'-Thiobis(4-(1,1,3,3-tetramethyl-n-butyl)- phenolato)(2,1)]-O,O',S-(1-butanamine), nickel II | kg | Free | | 15.4¡é/kg + 46.5% |
| 2942.00.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4¡é/kg + 46.5% |
| 3002.10.01 | 20 | Normal human blood sera, whether or not freeze-dried | kg | | | |
| 3002.90.51 | 10 | Whole human blood | kg | | | |
| 3004.90.10 | 00 | Containing antigens or hyaluronic acid or its sodium salt | kg | Free | | Free |
| 3103.10.00 | 10 | Normal and enriched superphosphates, less than 40 percent available phosphorus pentoxide (P2O5) equivalent | t | | | |
| 3103.10.00 | 20 | Concentrated superphosphates, 40 percent or more available phosphorus pentoxide (P2O5) equivalent | t | | | |
| 3201.10.00 | 00 | Quebracho extract | kg | Free | | Free |
| 3201.20.00 | 00 | Wattle extract | kg | Free | | Free |
| 3201.90.10 | 00 | Tannic acid, containing by weight 50 percent or more of tannic acid | kg | 1.5% | Free (A,AU,BH, CA,CL,E,IL,J,JO, MA,MX, P,SG) | 8% |
| 3204.11.35 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX,P) 3% (SG) | 63.5% |
| 3204.12.45 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A*,AU,BH, CA,CL,E,IL,J,JO, MA,MX,P) 3% (SG) | 72% |
| 3204.13.60 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX,P) 3% (SG) | 71.7% |
| 3204.14.30 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX,P) 3% (SG) | 67.3% |
| 3204.15.40 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX,P) 3% (SG) | 75.3% |
| 3204.16.30 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX,P) 3% (SG) | 63.8% |
